As India negotiates trade deals with other countries, one demand keeps coming back to the table — that drug regulators be barred, for a fixed number of years, from approving cheaper copies of a new medicine, even after its patent has expired.
The clause is called “data exclusivity”, and India has so far refused it. So far India has held its ground. It refused the UK’s demand for the clause in the free trade agreement announced on May 6, 2025. It had earlier turned down the same demand from the European Free Trade Association (EFTA) bloc of Iceland, Liechtenstein, Norway and Switzerland. The demand keeps returning, however, as India negotiates trade pacts with other partners.